Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II
Heterozygous loss of chromosome 17p is a common genomic event in castration-resistant prostate cancers (CRPC). Here, the authors use CRISPR-based screen to identify RBX1 as a target gene for CRPC with 17p loss and targeting RBX1 sensitizes CRPC to the treatment of α-amanitin antibody conjugates.
Guardado en:
Autores principales: | Yujing Li, Yunhua Liu, Hanchen Xu, Guanglong Jiang, Kevin Van der Jeught, Yuanzhang Fang, Zhuolong Zhou, Lu Zhang, Michael Frieden, Lifei Wang, Zhenhua Luo, Milan Radovich, Bryan P. Schneider, Yibin Deng, Yunlong Liu, Kun Huang, Bin He, Jin Wang, Xiaoming He, Xinna Zhang, Guang Ji, Xiongbin Lu |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4b210d41ca154f21b5a6e78a1b6ae6c9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
por: Yunhua Liu, et al.
Publicado: (2018) -
Amplification of USP13 drives ovarian cancer metabolism
por: Cecil Han, et al.
Publicado: (2016) -
PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
por: Tianrun Liu, et al.
Publicado: (2018) -
Erratum: A biomimetic hybrid nanoplatform for encapsulation and precisely controlled delivery of theranostic agents
por: Hai Wang, et al.
Publicado: (2016) -
Heterozygous diploid and interspecies SCRaMbLEing
por: Michael J. Shen, et al.
Publicado: (2018)